Please type a plus sign (+) inside this box

UTILITY PATENT APPLICATION **TRANSMITTAL**

Under the Paperwork Reduction Act of 1995, no persons are rec	quired to re	spond to a collection of	information unless it displays a val	id OMB control number	
UTILITY PATENT APPLICATION TRANSMITTAL	Attorn	ney Docket No.	LEX-0284-USA		
	First Inventor		Friddle, et al.		
	Title	Novel Human Ion the Same	Channel Protein and Polyn	ucleotidesa ncod	
for new nonprovisional applications under 37 CFR			E11 04 E05 E000 110	v. 6	

	.53 (b))	Express Mail Label No.	EV 0170758	320 US	58 3	
	TION ELEMENTS concerning utility patent application	ADDRESS TO: BO	ssistant Commis ox Patent Applic ashington, DC		10, 10,	
1. X Fee Transmittal F 2. X Applicant claims s See 37 CFR 1.27 Specification (preferred arrangement) - Descriptive title of the Cross Reference to Statement Regarding Reference to Sequel or a computer programment or a compu	rorm (e.g., PTO/SB/17) small entity status. . [Total Pages set forth below] 32] set Invention Related Applications g Fed sponsored R & D nnce listing, a table, ram listing appendix nvention Intervention Interv	8. Nucleotide and/or (if applicable, all r a. Compu b. Specification Sec i. X ii. X c. X Statem ACCOMPAN 9. Assignment F 10. 37 CFR 3.73(when there is 11. English Trans 12. Information D Statement (ID 13. Preliminary A 14. X Return Recei (Should be sy 15. Certified Cop (if foreign price) (b)(2)(B)(i). Or its equival	Amino Acid Specessary) ter Readable quence Listin diskette paper	pages g identity of above cop LICATION PARTS r sheet & document(s) t X Power of Attorney ment (if applicable) Copies of Citations MPEP 503) Mized) Document(s)	ies of IDS	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No.: Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
	19, CORRES	PONDENCE ADDRESS				
X Customer Number or Ba	(Insert Customer N	2,3A tach bar code label here)	or Con	respondence address belo	w	
Name Le	exicon Genetics Incorporate RADI	EMARK OFFICE				
4000 Research Forest Drive						
Address		TX	Γ	77004		
0.0	ne Woodlands State	Zip	77381			
Country U:	SA Telephon	281-863-3333	Fax	281-863-3335		
Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attor	ney/Agent)	41,866		
Signatura	Ema K. Sohumite py Daris	v. HBEER PEZING.41,071	Date	December 10, 2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

12/1	1031
0/01	U.S. PTO

1 12

ľŲ

lı să

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

Complete if Known				
Application Number	Not Yet Assigned			
Filing Date	December 10, 2001			
First Named Inventor	Friddle et al.			
Examiner Name	Not Yet Assigned			
Group Art Unit	Not Yet Assigned			
Attorney Docket No.	LEX-0284-USA			

TOTAL AMOUNT OF PAYMENT

ı	/¢\
1	(30)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

METHOD OF PAYMENT	FEE CALCULATION (continued)					
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES Large Small					
indicated fees and credit any overpayment to		ntity	E	Entity		
Account Number 50-0892	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Deposit Account Name	105	130	205	65	Surcharge - late fling fee or oath	
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127	50	227	25	Surcharge - late provisional filling fee or cover sheet	
Applicant claims small entity status. See 37 CFR 1.27	139	130	139	130	Non-English specification	
2. Payment Enclosed:	147	2,520	147	2,520	For filing a request for ex parte reexamination	
Check Credit card Money Order Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	113	1,840*	113	1,840*	Requesting publication of SIR after	
1. BASIC FILING FEE	115	110	215	55	Extension for reply within first month	
Large Small Entity	116	400	216	200	Extension for reply within second month	
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117	920	217	460	Extension for reply within third month	
101 740 201 370 Utility filing fee 370.00	118	1,440	218	720	Extension for reply within fourth month	
106 330 206 165 Design filing fee	128	1,960	228	980	Extension for reply within fifth month	
107 510 207 255 Plant filing fee	119	320	219	160	Notice of Appeal	
108 740 208 370 Reissue filing fee	120	320	220	160	Filing a brief in support of an appeal	į
114 160 214 80 Provisional filing fee	121	280	221	140	Request for oral hearing	
	138	1,510	138	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$)370.00	140	110	240	55	Petition to revive - unavoidable	
2. EXTRA CLAIM FEES	141	1,280	241	640	Petition to revive - unintentional	
Fee from Extra Claims below Fee Paid	142	1,280	242	640	Utility issue fee (or reissue)	
Total Claims -20**= X =	143	460	243	230	Design issue fee	
Independen -3**= X =	144	620	244	310	Plant issue fee	
Multiple Dependent =	122	130	122	130	Petitions to the Commissioner	
Large Entity Small Entity	123	50	123	50	Processing fee under 37 CFR 1.17(q)	
Fee Fee Fee Fee Fee Description	126	180	126	180	Submission of Information Disclosure Stmt	
103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent assignment per property (times number of properties)	
102 84 202 42 Independent claims in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
109 84 209 42 **Reissue independent claims over original patent	179	740	279	370	Request for Continued Examination (RCE)	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169	900	169	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$)	1	ee (spe				
**or number previously paid, if greater; For Reissues, see above	subto	ed by B	asic Filir 3)	ng Fee P	(\$)	

SUBMITTED BY Complete (if applicable)						
Name (Print/Type)	Lance K. Ishimoto	Registration No (Attorney/Agent)	41,866	Telephone	281-863-3042	
Signature				Date	December 10, 2001	

WARNING: Information on this form may become public. Credit card information should not be

included on this form. Provide credit card information of DTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Friddle et al.

U.S. Ser. No.:

To be assigned

Attorney Docket No.: LEX-0284-USA

Filing Date:

December 10, 2001

For:

Novel Human Ion Channel Protein and Polynucleotides Encoding the Same

VERIFIED STATEMENT

Box Patent Application Commission for Patents Washington, D.C. 20231

Sir:

- I, DRENDA D. THOMAS, do declare and state as follows:
- 1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.
- 2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,

December 10, 2001

Date

Drenda D. Thomas